{"id":"W2070500796","title":"Azapirone 5-HT<sub>1A</sub> receptor partial agonist treatment for major depressive disorder: systematic review and meta-analysis","authors":["Taro Kishi","H.Y. Meltzer","Yuki Matsuda","Nakao Iwata"],"venue":"Psychological Medicine","year":2013,"doi":"10.1017/s0033291713002857","url":"https://doi.org/10.1017/s0033291713002857","openalex":"https://openalex.org/W2070500796","abstract":"Background A meta-analysis of the serotonin 1A (5-HT 1A ) receptor partial agonist of the azapirone class as an anxiolytic drug for the treatment of major depressive disorder (MDD) has not previously been reported. Method We carried out a systematic review of the literature available in PubMed, the Cochrane Library database and PsycINFO up to 12 October 2013, and conducted a meta-analysis of randomized controlled trials (RCTs) comparing 5-HT 1A agonists with placebo and RCTs of 5-HT 1A agonist augmentation therapies for MDD treatment. We calculated the risk ratio (RR), number needed to treat (NNT)/number needed to harm (NNH) and 95% confidence intervals (CIs). Results Fifteen RCTs comparing 5-HT 1A agonists with placebo (total n = 2469, four studies with buspirone, seven with gepirone, three with ipsapirone and one with zalospirone) were identified. Pooled 5-HT 1A agonists had significantly more responders (RR 0.74, 95% CI 0.65â€“083, p &lt; 0.00001, NNT = 6, 12 trials, n = 1816) than placebo. Pooled 5-HT 1A agonists were superior to placebo in discontinuation due to inefficacy (RR 0.49, p = 0.02, NNH = 16, p = 0.03, 10 trials, n = 1494) but were inferior to placebo in discontinuation due to side-effects (RR 1.88, p &lt; 0.0001, NNH = 17, p = 0.001, 13 trials, n = 2196). However, all-cause discontinuation was similar in both groups (RR 0.99, p = 0.85, 14 trials, n = 2402). Four 5-HT 1A agonist augmentation studies were identified (total n = 365, three buspirone studies and one tandospirone study). There were no statistically significant effects of 5-HT 1A agonist augmentation therapies on response rate (RR 0.98, p = 0.85, four trials, n = 341). 5-HT 1A agonist-related side-effects including gastrointestinal symptoms, dizziness, insomnia, palpitation, paresthesia and sweating were greater than with placebo ( p &lt; 0.00001 to p = 0.03). Conclusions Our results suggest that 5-HT 1A agonist has a more beneficial effect on MDD than placebo, but has several side-effects.","is_oa":false,"oa_status":null,"network":{"internal_citations":0,"cited_by_count":37},"references":53,"networkCitations":0,"seed":false}